ASCO 2018 - Results from #120

Viewing 121-140 of 140 articles

ASCO 2018: Evaluating the Efficacy and Safety of the Oral CXCR4 Inhibitor X4P-001 in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma

ASCO 2018: Pegilodecakin with Nivolumab or Pembrolizumab in Patients with Metastatic Renal Cell Carcinoma

ASCO 2018: Pembrolizumab versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer: 2-Year Follow-Up from KEYNOTE-045 Trial

ASCO 2018: A Subgroup Analysis of the East Asia Population in RANGE

ASCO 2018: Risks versus Benefits: Using Social Media Safely

ASCO 2018: How I Do It: Precision Medicine for Prostate Cancer in the Real World

ASCO 2018: Prognostic Biomarkers in the "Precise" Management of Kidney Cancer

ASCO 2018: Atezolizumab in Special Populations: Analyses from an Expanded Access Program in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma

ASCO 2018: Clinical Applications of the Biology of Renal Cancer

ASCO 2018: First-Line Pembrolizumab in Cisplatin Ineligible Advanced Urothelial Cancer-KEYNOTE-052

ASCO 2018: Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

ASCO 2018: Bladder-Sparing Strategies in Bladder Cancer

ASCO 2018: Personalized Approach to the Management of Renal Cell Carcinoma

ASCO 2018: Next-Generation Sequencing—Is It Right for Every Patient?

ASCO 2018: Challenges of Perioperative Systemic Therapy of Localized Urothelial Cancer

ASCO 2018: Personalized Care in the Management of Kidney Cancer

ASCO 2018: Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer

ASCO 2018: Geriatric Assessment Improves Communication Between Oncologists and Older Patients

ASCO 2018: Abiraterone May Be More Effective in Black Men with Advanced Prostate Cancer than in White Men

ASCO 2018: Black Men with Advanced Prostate Cancer Treated with Chemotherapy May Have Equal or Better Survival than White Men

1
2
3
4
5
6
7